Can Conbercept completely cure macular disease?
Nov 19, 2025
Source: Cainiu Health
Dr. Huang Yuhong
Introduction
If macular disease is of the type wet age-related macular degeneration or diabetic macular edema, and is in the early stage of development with few retinal new blood vessels and mild edema, following a standardized treatment course with conbercept injections can effectively suppress neovascularization and reduce macular edema. This leads to significant improvement in the patient's vision, long-term disease stability, and maintenance of visual function necessary for normal daily life.
Under normal circumstances, conbercept may improve vision and control the progression of certain types of early-stage macular diseases, but it rarely achieves a complete cure. The effectiveness largely depends on the specific condition and its stage. If there are concerns, it is recommended to seek medical advice promptly. Detailed analysis is as follows:
If the macular disease is of types such as wet age-related macular degeneration or diabetic macular edema, and is in the early stages—with few new blood vessels in the retina and mild edema—regular, standardized intravitreal injections of conbercept according to the prescribed treatment course can effectively inhibit abnormal blood vessel growth and reduce macular swelling. In most patients, this leads to significant improvement in vision and long-term disease stability, preserving the visual function necessary for daily living.
However, if the macular disease has progressed to an advanced stage, with severe tissue atrophy or scar formation in the macular area of the retina, or if it is a type such as dry age-related macular degeneration that does not respond to this medication, conbercept cannot reverse the already damaged macular tissue. In these cases, the drug may only slow further progression but cannot achieve a complete cure, and the degree of vision improvement is often limited.
Treatment with conbercept must strictly follow medical instructions regarding injection timing and frequency; patients should not adjust the dosage or injection schedule on their own. Regular follow-up visits to the hospital are required during treatment to monitor fundus changes and visual acuity, allowing real-time assessment of disease progression. If symptoms such as eye pain or sudden vision loss occur, immediate medical evaluation is necessary.
